{"nctId":"NCT00669331","briefTitle":"Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis","startDateStruct":{"date":"2009-11"},"conditions":["Bronchiectasis"],"count":485,"armGroups":[{"label":"Mannitol","type":"EXPERIMENTAL","interventionNames":["Drug: Inhaled mannitol"]},{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matched control"]}],"interventions":[{"name":"Inhaled mannitol","otherNames":[]},{"name":"Matched control","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Have given written informed consent to participate in this study in accordance with local regulations\n2. Have documented evidence of confirmed diagnosis of (non-cystic fibrosis) bronchiectasis by computed tomography (CT), High resolution computed tomography (HRCT) or bronchogram\n3. Be aged 18 - 85 years inclusive, male and female\n4. Have FEV1 (Forced expiratory volume in one second) ≥ 40% and ≤85% predicted\\* and ≥1.0L (\\*according to NHANES III predicted tables) measured at Visit 0A (V0A)\n5. Clinician documented history of at least 2 pulmonary exacerbations, each requiring antibiotic therapy, in the last 12 months prior to Visit 0A (V0A) and a total of at least 4 in the last 2 years prior to Visit 0A\n6. Have a total SGRQ (St George's respiratory questionnaire) score of ≥30 at Visit 0B (V0B)\n7. Have a production of ≥10g of sputum at Visit 0B Have reported chronic sputum production of ≥1 tablespoon (15mL) per day on the majority of days in the 3 months prior to Visit 0A\n8. Be able to perform all the techniques necessary to measure lung function\n9. Have FEV1 ≥40% predicted\\* and ≥1.0L (\\*according to NHANES III 1999 predicted tables) measured at V0B (Baseline result prior to MTT (Mannitol Tolerance Test) administration)\n\nExclusion Criteria\n\n1. Be investigators, site personnel directly affiliated with this study, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.\n2. Have bronchiectasis as a consequence of cystic fibrosis or focal endobronchial lesion or otherwise curable causes (e.g. foreign body aspiration)\n3. Be considered \"terminally ill\" or listed for transplantation\n4. Be using hypertonic saline in the 14 days prior to commencing Visit 0B or thereafter at any time during the study\n5. Have previously used inhaled mannitol (Bronchitol) for more than a day\n6. Have had a significant episode of hemoptysis (\\>60 mL) in the previous 6 months\n7. Have had rescue antibiotics in the 4 weeks prior to V0B (chronic background antibiotic therapy accepted)\n8. Have smoked within the last 3 months and must not smoke during their participation in the study\n9. Have had a myocardial infarction in the three months prior to Visit 0A\n10. Have had a cerebral vascular accident in the three months prior to Visit 0A\n11. Have had major ocular surgery in the three months prior to Visit 0A\n12. Have had major abdominal, chest or brain surgery in the three months prior to Visit 0A\n13. Have a known cerebral, aortic or abdominal aneurysm\n14. Have actively treated Mycobacterium tuberculosis\n15. Have actively treated or unstable nontuberculous mycobacterial (NTM)infection or be under consideration for NTM treatment in the next 12 months\n16. Have unstable Allergic bronchopulmonary aspergillosis (ABPA) requiring steroid therapy (≤5mg dose oral steroids in stable ABPA accepted)\n17. Have end stage interstitial lung disease\n18. Have active malignancy including melanoma (other skin carcinomas exempted). Remissions from any malignancy ≥2 years also exempted\n19. Be breast feeding or pregnant, or plan to become pregnant while in the study\n20. Be using an unreliable form of contraception (female subjects at risk of pregnancy only)\n21. Be participating in another investigational drug study, parallel to, or within 4 weeks of Visit 0A\n22. Have a known intolerance to mannitol or β2-agonists\n23. Have uncontrolled hypertension - e.g. for adults: systolic blood pressure (BP) \\> 190 and or diastolic BP \\> 100\n24. Subject has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study\n25. Have previously been screen failed for the study (exceptions - see section 3.3.2 Eligibility Criteria - Rescreening)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Graded Pulmonary Exacerbations","description":"A graded pulmonary exacerbation was defined as a worsening in signs and symptoms requiring a change in treatment (Center for Drug Evaluation and Research (CDER), 2007). Grade I was required 3 main signs and symptoms, Grade II 2 main signs and symptoms and Grade III 1 main and one or more minor signs and symptoms. Main signs and symptoms were increased cough, sputum volume or sputum purulence. Minor were upper respiratory tract infection, fever, increased wheezing, increased dyspnea, increase in respiratory rate, increase in cardiac frequency of \\>20%, and increased malaise, fatigue or lethargy. Rate is defined as the number of all GPE events observed in one treatment year","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":null},{"groupId":"OG001","value":"2.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":null},{"groupId":"OG001","value":"1.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life as Measured by the St. Georges Respiratory Questionnaire (SGRQ) Total Score","description":"The SGRQ was collected at baseline, week 6, week 16, week 28, week 40 and week 52. Change in total score was calculated from baseline. Total scores are a weighted sum across all questions. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. Higher scores indicate lower quality of life. Outcome data table gives the raw mean total score at each visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.98","spread":"14.64"},{"groupId":"OG001","value":"52.22","spread":"14.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.09","spread":"17.49"},{"groupId":"OG001","value":"44.55","spread":"18.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.67","spread":"19.07"},{"groupId":"OG001","value":"44.23","spread":"19.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.45","spread":"18.58"},{"groupId":"OG001","value":"43.46","spread":"19.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.39","spread":"18.86"},{"groupId":"OG001","value":"43.51","spread":"19.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.43","spread":"19.60"},{"groupId":"OG001","value":"42.25","spread":"19.50"}]}]}]},{"type":"SECONDARY","title":"Antibiotic Use Prescribed for Treated Pulmonary Exacerbations","description":"Rate of antibiotic treated graded pulmonary exacerbations, using the same definition of a graded pulmonary exacerbation as the primary endpoint. A graded pulmonary exacerbation was considered to be anti-biotic treated if use of oral, IV or inhaled antibiotic use was recorded related to the GPE event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Graded Exacerbation","description":"Time to first graded exacerbation is defined as the duration (in months) from the randomisation date to the start of the first reported graded PE during the on-treatment period. Patients without reported graded PE event will be censored at the last participation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Graded Exacerbations","description":"Duration of graded exacerbations is defined as the number of days with graded PE within one treatment year. Mean days estimated via negative binomial model with treatment, region and baseline pulmonary exacerbation rate as predictors, with log of follow-up time as the offset variable","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.49","spread":null},{"groupId":"OG001","value":"35.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Sputum Volume","description":"24 hour sputum weight, measured at baseline, week 6, week 16, week 28, week 40, week 52","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.88","spread":"18.71"},{"groupId":"OG001","value":"28.96","spread":"19.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.97","spread":"23.17"},{"groupId":"OG001","value":"22.82","spread":"20.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.69","spread":"22.09"},{"groupId":"OG001","value":"20.25","spread":"16.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.92","spread":"25.66"},{"groupId":"OG001","value":"18.88","spread":"17.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.56","spread":"21.58"},{"groupId":"OG001","value":"18.17","spread":"16.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.54","spread":"24.07"},{"groupId":"OG001","value":"18.33","spread":"16.00"}]}]}]},{"type":"SECONDARY","title":"Daytime Sleepiness Scores","description":"Epworth Sleepiness Scale (ESS) score was calculated as the sum of scores for each of eight individual questions, such that a total score of zero represents no daytime sleepiness, and a total score of 24 represents the maximum degree of daytime sleepiness. Measured at baseline, 6 weeks, 16 weeks, 28 weeks, 40 weeks, 52 weeks","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.23","spread":"4.85"},{"groupId":"OG001","value":"6.89","spread":"4.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.07","spread":"4.78"},{"groupId":"OG001","value":"6.87","spread":"4.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.21","spread":"5.10"},{"groupId":"OG001","value":"6.50","spread":"4.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.05","spread":"4.73"},{"groupId":"OG001","value":"6.57","spread":"4.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.32","spread":"5.10"},{"groupId":"OG001","value":"6.33","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.09","spread":"4.98"},{"groupId":"OG001","value":"6.34","spread":"5.02"}]}]}]},{"type":"SECONDARY","title":"Lung Function - Change in FEV1 (Forced Expiratory Volume in One Second)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":null},{"groupId":"OG001","value":"-5.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Lung Function - Change in FVC (Forced Vital Capacity)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"-15.70","spread":null}]}]}]},{"type":"SECONDARY","title":"Lung Function - Change in FEV1/FVC","description":"FEV1 expressed as a ratio of FVC. Endpoint is expressed as a percentage ie FEV1/FVC\\*100","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Lung Function - Change in FEF25-75 (Forced Expiratory Flow Rate Averaged Over 25th -75th Percentile of FVC)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.21","spread":null},{"groupId":"OG001","value":"-3.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Profile - Sputum Microbiology","description":"sputum microbiology assessed as the presence of abnormal flora in sputum sample taken at any post baseline visit","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Profile - Clinical Chemistry","description":"Clinical chemistry was assessed as clinically significant abnormal liver function test and clinically significant abnormal urea/electrolyte test at any point post baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Profile - Hematology","description":"hematology assessed as clinically significant abnormal FBC (Full Blood count) at any point post baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"• (Exploratory) Number of Hospitalizations Due to Pulmonary Exacerbations","description":"Mean rate of hospitalisations (number/year) summarised and analysed to take account of differing follow-up times.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":null},{"groupId":"OG001","value":"0.20","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Health Related Costs of Treating Patients With Bronchiectasis","description":"In the presence of a significant primary endpoint, these data were intended to be derived using the trial data together with external information (Note as the primary objective of this study did not reach statistical significance, health related costs were not assessed)","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Health Status and Utility Scores","description":"In the presence of a significant primary endpoint, these data were intended to be derived from the trial data and external information (Note as the primary objective of this study did not reach statistical significance, differences in health status and utility scores were not assessed)","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Health Related Quality of Life (HRQL) and Quality Adjusted Life Years (QALYs) by Treatment Group Using Utility Scores From the Health Utilities Index Questionnaire","description":"In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, HRQL and QALYs were not collected).","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Cost Effectiveness of Treating Patients With Bronchiectasis With Inhaled Mannitol","description":"In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, cost effectiveness was not collected).","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":233},"commonTop":["Condition aggravated","Nasopharyngitis","Bacteia sputum identified","Headache","Cough"]}}}